초록 ▼

The expression of ubiquitin carboxy-terminal hydrolase is aberrent in cells that are resistant to treatment with chemical agents. Accordingly, the invention features methods for diagnosing and treating drug resistant cells (e.g., tumor cells) by examining and modulating the expression or activity of

The expression of ubiquitin carboxy-terminal hydrolase is aberrent in cells that are resistant to treatment with chemical agents. Accordingly, the invention features methods for diagnosing and treating drug resistant cells (e.g., tumor cells) by examining and modulating the expression or activity of UCH.

대표청구항 ▼

[ What is claimed is:] [1.] A method of determining whether a transformed mammalian cell will respond to a pharmaceutical agent, the method comprising(a) determining the level of activity of ubiquitin carboxy-terminal hydrolase in said transformed cell,(b) comparing the level of activity of ubiquiti

[ What is claimed is:] [1.] A method of determining whether a transformed mammalian cell will respond to a pharmaceutical agent, the method comprising(a) determining the level of activity of ubiquitin carboxy-terminal hydrolase in said transformed cell,(b) comparing the level of activity of ubiquitin carboxy-terminal hydrolase in said transformed cell with the level of activity of ubiquitin carboxy-terminal hydrolase in a nontransformed cell of the same type, and(c) identifying said transformed cell as being resistant to a pharmaceutical agent when there is an increased level of activity of ubiquitin carboxy-terminal hydrolase in said transformed cell compared to said nontransformed cell.